SCHEMBL2934546

SCHEMBL2934546

CN1CCN(C(=O)c2ccc(-c3cncc(-c4ccc(O)cc4)n3)c(F)c2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
MKNK1 Q9BUB5 4/20 0.49
MKNK2 Q9HBH9 4/20 0.49
CHEK1 O14757 3/20 0.48
ADORA2A P29274 1/20 0.46
ADORA1 P30542 1/20 0.46
MAP4K1 Q92918 1/20 0.44
KCNH2 Q12809 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
CYP2C9 P11712 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
POLB P06746 1/20 0.43
STAT3 P40763 1/20 0.42
ACACB O00763 1/20 0.42
ACACA Q13085 1/20 0.42
ATR Q13535 1/20 0.42
CDK6 Q00534 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2936083 0.88 MKNK1 (0.50) MEN1KMT2AMKNK1MKNK2CHEK1
SCHEMBL2927597 0.79 KDR (0.58) MEN1KMT2AMAP4K1HPGDTSHR
SCHEMBL13515277 0.78 FASN (0.50) MEN1KMT2AMKNK1MKNK2CHEK1
SCHEMBL2932525 0.77 LRRK2 (0.46) MKNK1MKNK2CHEK1ATR
SCHEMBL13515300 0.77 MKNK1 (0.46) KMT2AMKNK1MKNK2CHEK1ALDH1A1
SCHEMBL2931418 0.77 SRC (0.49) KMT2AMKNK1MKNK2ALDH1A1ATR
SCHEMBL13515311 0.76 PIM3 (0.54) MKNK1MKNK2CHEK1KCNH2HPGD
SCHEMBL2934437 0.76 TTK (0.52)
Trifluoroacetic Acid SCHEMBL2931457 0.75 FASN (0.46) MKNK1MKNK2CHEK1KCNH2HPGD
Trifluoroacetic Acid SCHEMBL2935027 0.74 MKNK1 (0.41) MKNK1MKNK2CHEK1KCNH2STAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
CN-101472912-A Pyridine and pyrazine derivatives as MNK kinase inhibitors BIOVITRUM AB PUBL (SE) 2009-07-01 CN disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
WO-2007147874-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (PUBL) (SE) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039450-A1 Compounds NEK2, CSNK2A3, CSNK2A1 MEN1 456/4885KMT2A 950/4885MKNK1 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.